A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

Prometic Biotherapeutics

Status

Conditions: Hypoplasminogenemia

Treatments: Biological: Plasminogen (Human)

Study type: Expanded Access

Funder types: Other; Industry

Identifiers

NCT03265171

2002C013G

Details and patient eligibility

About

These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia. These patients are under treatment to address wound healing and obstructions.

Sex: All

Ages: 16+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient has provided informed consent.
• Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract.

Exclusion criteria

• Not applicable